Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis

Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy

“…Most of the studies refer that therapy failure occurred more frequently in positive anti-drug Ab patients [3,32,37,39], although there are previous reports which did not find a similar relation [40][41][42]. It is also reported that the concomitant use of MTX with anti-TNFα drugs reduces the incidence of anti-drug Ab [6,36]; in our study, in agreement with opposite results [13,39] concomitant MTX therapy was irrelevant on anti-drug Ab development.…”

“…ETN has shown a less immunogenic effect with anti-etanercept antibodies (anti-ETN Ab) not detectable or present only in a low number of patients; as a consequence anti-ETN immune response has a minimal effect on clinical response [4,[7][8][9]. A clinically relevant impact of anti-drug Ab is described in about half of the patients receiving repeated TNFα monotherapy and therefore immune suppression by concomitant administration of metrotrexate (MTX) is indicated in RA and SpA patients [8,[10][11][12][13][14][15][16][17][18][19][20][21]. Detectable anti-drug Ab decrease TNFα blockers response by as much as 80% [22].…”

Suivi thérapeutique pharmacologique des anti-TNF-α au cours des spondyloarthrites

“…Les données disponibles comparant l'infliximab seul et son association au MTXe sont rare et contradictoires [8,9]. Actuellement, selon la Société franç aise de rhumatologie, il n'existe pas de preuve de l'intérêt d'associer un DMARD pour améliorer l'effet des biomédicaments anti-TNF-␣ dans la SpA [10].…”

Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?

“…Pérez-Guijo et al 5 have previously investigated the potential value of infliximab and methotrexate in comparison to infliximab alone for the treatment of patients with AS. In their openlabel, nonrandomized trial, the nine patients who were administered methotrexate and infliximab responded better than the ten patients given infliximab alone; however, the patients in the combination therapy group were also significantly younger and had shorter disease duration, which are both known predictors for a good response to tumor necrosis factor blockers.…”